BioNexus Gene Lab Corp. Acquires 15% Stake in Fidelion Diagnostics

Reuters12-03

<a href="https://laohu8.com/S/BGLC">BioNexus Gene Lab Corp.</a> Acquires 15% Stake in Fidelion Diagnostics

BioNexus Gene Lab Corp. has completed a strategic equity investment in Fidelion Diagnostics Pte. Ltd., acquiring a 15% minority stake through a non-cash share swap. In return, Fidelion now holds approximately 16.6% of BioNexus Gene Lab Corp.'s issued and outstanding stock, aligning the interests of both companies. As part of the agreement, BioNexus Gene Lab Corp. also secured exclusive commercial rights to the VitaGuard™ Tumor-Naïve Minimal Residual Disease (MRD) liquid biopsy platform for Southeast Asia via a licensing agreement, with the license fee payable over 24 monthly installments. The deal is designed to preserve financial strength, minimize dilution, and support BioNexus Gene Lab Corp.'s expansion in the precision oncology market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNexus Gene Lab Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596053-en) on December 03, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588041193?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-03 21:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588041193","market":"fut","top_or_hot":-1,"title":"BioNexus Gene Lab Corp. Acquires 15% Stake in Fidelion Diagnostics","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BGLC\">BioNexus Gene Lab Corp.</a> Acquires 15% Stake in Fidelion Diagnostics\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioNexus Gene Lab Corp. has completed a strategic equity investment in Fidelion Diagnostics Pte. Ltd., acquiring a 15% minority stake through a non-cash share swap. In return, Fidelion now holds approximately 16.6% of BioNexus Gene Lab Corp.'s issued and outstanding stock, aligning the interests of both companies. As part of the agreement, BioNexus Gene Lab Corp. also secured exclusive commercial rights to the VitaGuard™ Tumor-Naïve Minimal Residual Disease (MRD) liquid biopsy platform for Southeast Asia via a licensing agreement, with the license fee payable over 24 monthly installments. The deal is designed to preserve financial strength, minimize dilution, and support BioNexus Gene Lab Corp.'s expansion in the precision oncology market.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNexus Gene Lab Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596053-en) on December 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNexus Gene Lab Corp. Acquires 15% Stake in Fidelion Diagnostics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNexus Gene Lab Corp. Acquires 15% Stake in Fidelion Diagnostics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-03 21:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BGLC\">BioNexus Gene Lab Corp.</a> Acquires 15% Stake in Fidelion Diagnostics\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioNexus Gene Lab Corp. has completed a strategic equity investment in Fidelion Diagnostics Pte. Ltd., acquiring a 15% minority stake through a non-cash share swap. In return, Fidelion now holds approximately 16.6% of BioNexus Gene Lab Corp.'s issued and outstanding stock, aligning the interests of both companies. As part of the agreement, BioNexus Gene Lab Corp. also secured exclusive commercial rights to the VitaGuard™ Tumor-Naïve Minimal Residual Disease (MRD) liquid biopsy platform for Southeast Asia via a licensing agreement, with the license fee payable over 24 monthly installments. The deal is designed to preserve financial strength, minimize dilution, and support BioNexus Gene Lab Corp.'s expansion in the precision oncology market.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNexus Gene Lab Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596053-en) on December 03, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210149790.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL3sWBGT:1","article_id":"2588041193","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588041193","pubTimestamp":1764769516,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BioNexus Gene Lab Corp. has completed a strategic equity investment in Fidelion Diagnostics Pte. Ltd., acquiring a 15% minority stake through a non-cash share swap. In return, Fidelion now holds approximately 16.6% of BioNexus Gene Lab Corp.'s issued and outstanding stock, aligning the interests of both companies. As part of the agreement, BioNexus Gene Lab Corp. also secured exclusive commercial rights to the VitaGuard Tumor-Nave Minimal Residual Disease  liquid biopsy platform for Southeast Asia via a licensing agreement, with the license fee payable over 24 monthly installments. The deal is designed to preserve financial strength, minimize dilution, and support BioNexus Gene Lab Corp.'s expansion in the precision oncology market.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interprete","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4104":"贸易公司与经销商","BGLC":"BioNexus Gene Lab Corp.","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NDAQ":"纳斯达克OMX交易所","BK4588":"碎股"},"translate_title":"BioNexus Gene Lab Corp.收购Fidelion Diagnostics 15%的股份","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BGLC":0.9,"NDAQ":0.9},"content_text":"BioNexus Gene Lab Corp. Acquires 15% Stake in Fidelion Diagnostics\n    \n\n        BioNexus Gene Lab Corp. has completed a strategic equity investment in Fidelion Diagnostics Pte. Ltd., acquiring a 15% minority stake through a non-cash share swap. In return, Fidelion now holds approximately 16.6% of BioNexus Gene Lab Corp.'s issued and outstanding stock, aligning the interests of both companies. As part of the agreement, BioNexus Gene Lab Corp. also secured exclusive commercial rights to the VitaGuard™ Tumor-Naïve Minimal Residual Disease (MRD) liquid biopsy platform for Southeast Asia via a licensing agreement, with the license fee payable over 24 monthly installments. The deal is designed to preserve financial strength, minimize dilution, and support BioNexus Gene Lab Corp.'s expansion in the precision oncology market.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNexus Gene Lab Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596053-en) on December 03, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588041193","isCrawlerRequest":true}